Drug details

Kimyrsa (oritavancin for injeciton)

type of Glycopeptides

Kimyrsa (oritavancin) is a lipoglycopeptide antibacterial drug used to treat adult patients with acute bacterial skin and skin structure infections caused or suspected to be caused by susceptible isolates of designated Gram-positive microorganisms.

This drug may have the following side effects:

• nausea,
• itching,
• vomiting,
• fever,
• chills,
• dizziness,
• diarrhea
• headache,
• hypersensitivity,
• fast heart rate
• infusion site reaction,
• increased alanine aminotransferase,
• increased aspartate aminotransferase, and
• limb and subcutaneous abscesses,
• infusion site phlebitis,

The following drugs are related to Kimyrsa, either as a replacement or used together:

• Zovirax (acyclovir)
• Zovirax Suspension (acyclovir)
• Zovirax Cream (acyclovir cream, 5%)
• Zovirax Injection (acyclovir for injection)
• Zovirax Ointment (acyclovir ointment)
• Humira (adalimumab injection solution for subcutaneous administration)
• Amjevita (adalimumab-atto)
• Otezla (apremilast tablets)
• Siliq (brodalumab injection for subcutaneous use)
• Cosentyx (secukinumab injection)
• Enbrel (etanercept)
• Erelzi (etanercept-szzs injection)
• Famvir (famciclovir)
• Tremfya (guselkumab for injection)
• Ilumya (tildrakizumab-asmn injection, for subcutaneous use)
• Remicade (infliximab)
• Taltz (ixekizumab injection, for subcutaneous use)
• Skyrizi (risankizumab-rzaa injection)
• Stelara Injection (ustekinumab)
• Valtrex (valacyclovir hydrochloride)
• Vancocin (vancocin)